The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

DART4MM study: Can daratumumab consolidation achieve MRD-negativity after frontline therapy?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Alessandro Gozzetti, University of Siena, Siena, IT. We asked, Can daratumumab consolidation achieve MRD-negativity after frontline therapy?

DART4MM study: Can daratumumab consolidation achieve MRD-negativity after frontline therapy?

Gozzetti presents key results from the single-arm DART4MM study, observing long-term MRD-negativity over 1 year in patients with multiple myeloma treated with an anti-CD38 antibody, daratumumab, following autologous stem cell transplantation.


Share: